Overview Dividends

(VEEV) Veeva Systems - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9224751084

Cloud CRM, Data, Clinical, Regulatory

Health Care Technology
Market Cap in USD: 40,003m

IPO / Inception: 2013-10-16
Return 12m vs S&P 500: -7.62%

EPS (Earnings per Share)

EPS CAGR: 24.39%
EPS Trend: 90.2%

Last SUE: 1.54
Qual. Beats: 13

Revenue

Rev. CAGR: 14.67%
Rev. Trend: 98.7%

Last SUE: 1.91
Qual. Beats: 8

Dividends

Currently no dividends paid

Risk via 10d forecast
Volatility	34.2%
Value at Risk 5%th	47.1%
Relative Tail Risk	-16.29%

Reward TTM
Sharpe Ratio	0.22
Alpha	0.11
CAGR/Max DD	0.30

Character TTM
Hurst Exponent	0.572
Beta	0.602
Beta Downside	0.625

Drawdowns 3y
Max DD	26.99%
Mean DD	9.22%
Median DD	8.08%

Description: VEEV Veeva Systems September 29, 2025

Veeva Systems Inc. (NYSE: VEEV) delivers cloud-based software solutions tailored to the life-sciences sector across North America, Europe, APAC, the Middle East, Africa, and Latin America. Its flagship offering, the Veeva Commercial Cloud, bundles the Vault CRM Suite for pharma and biotech firms, Veeva Medical for multi-channel medical content, PromoMats for digital asset management, and Crossix for brand-level analytics.

The Veeva Data Cloud adds OpenData (customer reference data), Link (deep data integration), Compass (de-identified longitudinal patient data), and CRM Pulse (multichannel engagement metrics). The Veeva Development Cloud supports clinical trial execution (Clinical Platform, Clinical Data Management), safety and regulatory processes (Safety, RIM), and the Quality Cloud serves both life-sciences and consumer-products companies. Veeva also provides Business Consulting and a suite of professional services ranging from implementation to ongoing managed services.

Founded in 2007 (originally Verticals onDemand) and headquartered in Pleasanton, California, Veeva has become the de-facto SaaS provider for pharma, commanding a market-share advantage in a sector where cloud adoption is projected to grow at ~15% CAGR through 2028.

Key performance indicators from FY 2023 show total revenue of $2.1 billion, a 22% year-over-year increase, and an operating margin of roughly 30%; subscription-based ARR grew 26% YoY and the company reports a net-retention rate above 95%, underscoring strong customer stickiness.

Macro-level drivers include rising global R&D spend, heightened regulatory scrutiny that favors compliant cloud platforms, and the broader digital transformation of drug discovery, clinical trials, and commercial operations.

For a deeper dive into VEEV’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven overview.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (860.3m TTM) > 0 and > 6% of Revenue (6% = 184.8m TTM)

FCFTA 0.17 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 200.2% (prev 172.8%; Δ 27.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 1.38b > Net Income 860.3m (YES >=105%, WARN >=100%)

Net Debt (-1.57b) to EBITDA (908.7m) ratio: -1.73 <= 3.0 (WARN <= 3.5)

Current Ratio 7.53 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (168.0m) change vs 12m ago 1.80% (target <= -2.0% for YES)

Gross Margin 75.67% (prev 73.93%; Δ 1.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 42.34% (prev 41.17%; Δ 1.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3.26 (EBITDA TTM 908.7m / Interest Expense TTM -263.2m) >= 6 (WARN >= 3)

Altman Z'' 11.55

(A) 0.76 = (Total Current Assets 7.11b - Total Current Liabilities 944.9m) / Total Assets 8.10b

(B) 0.51 = Retained Earnings (Balance) 4.12b / Total Assets 8.10b

(D) 3.91 = Book Value of Equity 4.13b / Total Liabilities 1.06b

Total Rating: 11.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.73

1. Piotroski 4.50pt

2. FCF Yield 4.05%

3. FCF Margin 43.98%

4. Debt/Equity 0.01

5. Debt/Ebitda -1.73

6. ROIC - WACC (= 2.15)%

7. RoE 13.38%

8. Rev. Trend 98.70%

9. EPS Trend 90.19%

What is the price of VEEV shares?

As of November 28, 2025, the stock is trading at USD 240.67 with a total of 1,876,610 shares traded.
Over the past week, the price has changed by -11.03%, over one month by -18.61%, over three months by -18.03% and over the past year by +6.13%.

Is VEEV a buy, sell or hold?

Veeva Systems has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy VEEV.

Strong Buy: 12
Buy: 7
Hold: 11
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the VEEV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	316.8	31.6%
Analysts Target Price	316.8	31.6%
ValueRay Target Price	241.4	0.3%

VEEV Fundamental Data Overview November 23, 2025

Market Cap USD = 40.00b (40.00b USD * 1.0 USD.USD)
P/E Trailing = 47.575
P/E Forward = 31.746
P/S = 13.4772
P/B = 6.6787
P/EG = 1.2475
Beta = 1.04
Revenue TTM = 3.08b USD
EBIT TTM = 858.9m USD
EBITDA TTM = 908.7m USD
Long Term Debt = 75.8m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 89.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.57b USD (from netDebt column, last quarter)
Enterprise Value = 33.46b USD (40.00b + Debt 89.8m - CCE 6.64b)
Interest Coverage Ratio = -3.26 (Ebit TTM 858.9m / Interest Expense TTM -263.2m)
FCF Yield = 4.05% (FCF TTM 1.35b / Enterprise Value 33.46b)
FCF Margin = 43.98% (FCF TTM 1.35b / Revenue TTM 3.08b)
Net Margin = 27.93% (Net Income TTM 860.3m / Revenue TTM 3.08b)
Gross Margin = 75.67% ((Revenue TTM 3.08b - Cost of Revenue TTM 749.5m) / Revenue TTM)
Gross Margin QoQ = 75.41% (prev 75.26%)
Tobins Q-Ratio = 4.13 (Enterprise Value 33.46b / Total Assets 8.10b)
Interest Expense / Debt = 33.69% (Interest Expense 30.2m / Debt 89.8m)
Taxrate = 24.48% (76.6m / 312.8m)
NOPAT = 648.6m (EBIT 858.9m * (1 - 24.48%))
Current Ratio = 7.53 (Total Current Assets 7.11b / Total Current Liabilities 944.9m)
Debt / Equity = 0.01 (Debt 89.8m / totalStockholderEquity, last quarter 7.04b)
Debt / EBITDA = -1.73 (Net Debt -1.57b / EBITDA 908.7m)
Debt / FCF = -1.16 (Net Debt -1.57b / FCF TTM 1.35b)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.63% (Net Income 860.3m / Total Assets 8.10b)
RoE = 13.38% (Net Income TTM 860.3m / Total Stockholder Equity 6.43b)
RoCE = 13.20% (EBIT 858.9m / Capital Employed (Equity 6.43b + L.T.Debt 75.8m))
RoIC = 10.42% (NOPAT 648.6m / Invested Capital 6.23b)
WACC = 8.27% (E(40.00b)/V(40.09b) * Re(8.23%) + D(89.8m)/V(40.09b) * Rd(33.69%) * (1-Tc(0.24)))
Discount Rate = 8.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.27%
[DCF Debug] Terminal Value 79.61% ; FCFE base≈1.23b ; Y1≈1.42b ; Y5≈2.01b
Fair Price DCF = 204.3 (DCF Value 33.49b / Shares Outstanding 163.9m; 5y FCF grow 17.99% → 3.0% )
EPS Correlation: 90.19 | EPS CAGR: 24.39% | SUE: 1.54 | # QB: 13
Revenue Correlation: 98.70 | Revenue CAGR: 14.67% | SUE: 1.91 | # QB: 8

Additional Sources for VEEV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle